Recent Updates — FOXOW

Foxo Technologies Inc.'s majority stockholder approved a board authorization to effect a reverse stock split of Class A Common Stock at a ratio between one-for-fifty and one-for-one-thousand before June 30, 2027. The Board retains sole discretion to determine the exact ratio within this range without further shareholder approval. This action is intended to facilitate an application for uplisting to Nasdaq or NYSE American. A preliminary Information Statement was filed on August 14, 2026, with definitive materials to be mailed shortly thereafter; the split will become effective no earlier than 20 days after mailing and following FINRA Rule 6490 processing. Foxo Technologies Inc. operates in the cannabis technology sector.

FOXO Technologies Inc. subsidiary Vector BioSource, Inc. entered into an asset purchase agreement with Grifols Bio Supplies, Inc. to acquire four U.S.-based blood collection centers for $3,500,000 in cash plus a contingent earn-out of up to $1,000,000 based on EBITDA performance between 2026 and 2028. The transaction is subject to regulatory approvals including new FDA and CLIA certifications. FOXO Technologies Inc. operates in the biotechnology and life sciences sector, focusing on blood collection and biological asset management.